A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

Erlotinib should be considered for first-line treatment in this subset of Japanese patients, with close monitoring for ILD-like events.